685 related articles for article (PubMed ID: 27005620)
1. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
[TBL] [Abstract][Full Text] [Related]
2. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.
Lonardo A; Ballestri S; Guaraldi G; Nascimbeni F; Romagnoli D; Zona S; Targher G
World J Gastroenterol; 2016 Nov; 22(44):9674-9693. PubMed ID: 27956792
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
[TBL] [Abstract][Full Text] [Related]
4. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.
Adinolfi LE; Rinaldi L; Guerrera B; Restivo L; Marrone A; Giordano M; Zampino R
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27231906
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
6. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
[TBL] [Abstract][Full Text] [Related]
8. Steatosis and NASH in type 2 diabetes.
Hu M; Phan F; Bourron O; Ferré P; Foufelle F
Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
[TBL] [Abstract][Full Text] [Related]
9. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C and diabetes: the inevitable coincidence?
Lonardo A; Adinolfi LE; Petta S; Craxì A; Loria P
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):293-308. PubMed ID: 19344243
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease and hepatitis C infection.
Bondini S; Younossi ZM
Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
[TBL] [Abstract][Full Text] [Related]
12. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
15. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
16. [Pathogenesis of non-alcoholic fatty liver disease].
Anty R; Gual P
Presse Med; 2019 Dec; 48(12):1468-1483. PubMed ID: 31767252
[TBL] [Abstract][Full Text] [Related]
17. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
Targher G; Marchesini G; Byrne CD
Diabetes Metab; 2016 Jun; 42(3):142-56. PubMed ID: 27142870
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection.
Goossens N; Negro F
Rev Recent Clin Trials; 2014; 9(3):204-9. PubMed ID: 25514907
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
Gastaldelli A
Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
